Last reviewed · How we verify
Biosimilars vs generics
The fundamental difference: small molecule vs biologic
A small molecule is a chemically synthesised compound (atorvastatin, omeprazole) under ~1kDa. Manufacturing produces an identical molecule batch after batch. A biologic is a protein, antibody, peptide, or living cell typically 10–150 kDa (adalimumab, pembrolizumab, ozempic) produced by living cells. Manufacturing produces molecules that are similar but not identical because biology can't be reduced to a chemical formula — different cell lines, fermentation conditions, and purification steps produce subtly different protein forms.
Generic approval pathway
Generics are approved via the FDA's Abbreviated New Drug Application (ANDA) under the Hatch-Waxman Act of 1984. The sponsor must demonstrate bioequivalence (pharmacokinetic equivalence within tight bounds) and identical chemical composition. No clinical trials in patients are required. Approval typically takes 18–24 months. The legal bar is low; the regulatory bar is verification of identity.
Biosimilar approval pathway
Biosimilars are approved via the FDA's 351(k) BLA under the Biologics Price Competition and Innovation Act (BPCIA) of 2009. Sponsors must demonstrate biosimilarity through analytical similarity studies, pharmacokinetic + pharmacodynamic equivalence, and at least one comparative clinical trial in patients. Approval typically takes 5–8 years and costs $100M-$300M to develop. The bar is much higher than generics.
Interchangeability
A biosimilar is interchangeable if a pharmacist can substitute it for the originator without prescriber approval (analogous to a generic substitution). Most biosimilars are NOT interchangeable — the FDA requires additional switching-study data. This is a major US regulatory distinction; in most other countries biosimilars are automatically substitutable.
Pricing dynamics
Generics typically launch at 60–80% discount to the originator, dropping to 90%+ within 2 years as multiple manufacturers enter. Biosimilars typically launch at 15–35% discount (much smaller) because the development cost is higher, manufacturing is more complex, and switching friction is real. The market structure favours the originator longer.
Examples of each
Generics: atorvastatin (Lipitor → generic), sildenafil (Viagra → generic), omeprazole (Prilosec → generic). Biosimilars: adalimumab biosimilars (Humira → Cyltezo, Amjevita, Hadlima, others), trastuzumab biosimilars (Herceptin → Ogivri, Herzuma, Trazimera), pegfilgrastim biosimilars (Neulasta → Fulphila, Udenyca, Stimufend).
FAQ
Are biosimilars safe?
Yes. Approved biosimilars meet rigorous FDA + EMA biosimilarity standards including analytical, pharmacokinetic, and clinical comparability. They have similar safety profiles to the originator.
Why don't we have generic Humira?
Humira is a biologic, so technically there's no "generic" — only biosimilars. There are 10+ Humira biosimilars approved in the US/EU. They cost less than Humira but more than a typical small-molecule generic.
Can I switch from a biologic to its biosimilar?
In most countries, yes — the biosimilar is automatically substituted. In the US, your prescriber must specifically choose the biosimilar unless it's designated "interchangeable" (which is rare). Switching studies show no clinically meaningful differences for the major originators.
When will the next big patent cliff happen?
See our /patents tracker for year-by-year forecasts. Major upcoming cliffs: ustekinumab (Stelara), denosumab (Prolia/Xgeva), aflibercept (Eylea) 2024-26.